Faced in particular with the rise in power of the Delta variant, Pfizer will ask the American and European health authorities for authorization to administer a third dose of its reminder vaccine.
The American laboratory considers in its request to health authorities, that its Pfizer/BionTech vaccine remains very effective against the Delta variant, but after six months, there is a risk that the protection conferred by antibodies will no longer be as efficient, especially in the elderly.
This recall dose aims to ensure reinforced immune protection for people already vaccinated with two first doses. “Pfizer and Biontech have noted encouraging results of current trials for a third dose of the current vaccine,” it was said.
They “plan to submit these data to the FDA, EMA and other regulatory authorities in the coming weeks,” they added in reference to the American and European drugs of drugs.
